Equity Profile

IBRX

ImmunityBio, Inc.

Health CareBiotechnology$7.2B

Mar24Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products effectively.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IBRX Q2-2026 Earnings Preview

Context

Company Snapshot

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases. Operating in the health care sector, its innovations could significantly impact patient outcomes and treatment options in a competitive industry.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-72.64%

Avg Stock Reaction

-0.28%

Last Quarter Recap

In Q1-2026, ImmunityBio reported an EPS of -$0.62, missing analyst expectations significantly. The stock reacted negatively, dropping 7.4% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's recent performance and lack of guidance. The market is looking for signs of improvement in EPS and revenue.

Bull Case

If ImmunityBio can demonstrate progress in its clinical trials or announce new partnerships, it could lead to a positive shift in investor sentiment and stock price.

Bear Case

Continued losses and failure to meet expectations could further erode investor confidence, leading to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated outlook on clinical trial progress and potential commercialization timelines?

Any delays or advancements in trials could significantly impact future revenue and investor confidence.

How is the company addressing its recent financial performance and what measures are being taken to improve profitability?

Investors will be looking for concrete steps to mitigate losses and enhance financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ImmunityBio's recent clinical advancements to translate into improved financial performance this quarter.

Supporting Evidence

The company's history of beating EPS estimates 63% of the time suggests potential for a positive surprise.

Options pricing indicates a significant expected move, which could reflect investor anticipation of better-than-expected news.

Key Risk

If the company can show progress in its clinical trials, it could significantly alter the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its financial performance amid ongoing clinical developments.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$0.70 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±7.9%

Historical Avg

±7.9%

In line with history

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.9% while IBRX has averaged ±7.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

1.0%

30d HV

77.0%

Calls (1.2M)P/C Ratio: 0.47Puts (406K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing in-line setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ImmunityBio beats expectations, history suggests the stock could rise around 1.3% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await more clarity from management.

Miss

A miss could lead to a decline of about 1.3% based on historical patterns, reinforcing negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial results and timelines.
2Any new partnerships or collaborations that could enhance revenue.
3Management's strategy for addressing recent financial losses.
4Details on cost-cutting measures or operational improvements.
5Insights into market demand for ImmunityBio's products.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Energy Fuels Inc.

Company Snapshot

ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapy treatments for cancer and infectious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercialize its products effectively.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IBRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-72.64%

Avg Stock Reaction

-0.28%

Last Quarter Recap

In Q1-2026, ImmunityBio reported an EPS of -$0.62, missing analyst expectations significantly. The stock reacted negatively, dropping 7.4% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, given the company's recent performance and lack of guidance. The market is looking for signs of improvement in EPS and revenue.

Bull Case

If ImmunityBio can demonstrate progress in its clinical trials or announce new partnerships, it could lead to a positive shift in investor sentiment and stock price.

Bear Case

Continued losses and failure to meet expectations could further erode investor confidence, leading to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated outlook on clinical trial progress and potential commercialization timelines?

Any delays or advancements in trials could significantly impact future revenue and investor confidence.

How is the company addressing its recent financial performance and what measures are being taken to improve profitability?

Investors will be looking for concrete steps to mitigate losses and enhance financial health.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for ImmunityBio's recent clinical advancements to translate into improved financial performance this quarter.

Supporting Evidence

The company's history of beating EPS estimates 63% of the time suggests potential for a positive surprise.

Options pricing indicates a significant expected move, which could reflect investor anticipation of better-than-expected news.

Key Risk

If the company can show progress in its clinical trials, it could significantly alter the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to turn around its financial performance amid ongoing clinical developments.

Bull Confirmed If

A reduction in EPS losses to below -$0.50 would signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$0.70 would confirm ongoing financial struggles.

Pre-Earnings Positioning

Options Market

Implied Move

±7.9%

Historical Avg

±7.9%

In line with history

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±7.9% while IBRX has averaged ±7.9% over the last 8 prints — setup is roughly in line with history.

Detail

ATM IV

1.0%

30d HV

77.0%

Calls (1.2M)P/C Ratio: 0.47Puts (406K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing in-line setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If ImmunityBio beats expectations, history suggests the stock could rise around 1.3% on the day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await more clarity from management.

Miss

A miss could lead to a decline of about 1.3% based on historical patterns, reinforcing negative sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on clinical trial results and timelines.
2Any new partnerships or collaborations that could enhance revenue.
3Management's strategy for addressing recent financial losses.
4Details on cost-cutting measures or operational improvements.
5Insights into market demand for ImmunityBio's products.